Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 493

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1C
Chunk 493
---
 or 125%
of the closing price of the Company’s common stock on the day prior to closing. The Company received total net proceeds of $682,510
from the Offering. To date, the warrants from the Offering have yet to be exercised.

On
October 31, 2024, the Company consummated a public offering of an aggregate of (i) 395,574 Shares of
common stock, and 2,555,246 Pre-Funded Warrants to purchase up to 2,555,246 shares of common stock, and (ii) 2,950,820 Common Warrants
to purchase up to 2,950,820 Common Warrant Shares. Each share of common stock, or Pre-Funded Warrant in lieu thereof, was sold together
with an accompanying Common Warrant to purchase one share of common stock. The public offering price for each share of common stock and
one accompanying Common Warrant was $1.525. The public offering price of each Pre-Funded Warrant and one accompanying Common Warrant
was $1.524, which equals the price at which one share of common stock and accompanying Common Warrant was sold to the public in the offering,
minus $0.001. The exercise price of each Pre-Funded Warrant is $0.001 per share. Each Common Warrant offered in the offering is exercisable
for one share of common stock and has an initial exercise price equal to $1.40. The Company received aggregate gross proceeds from the
offering of approximately $4.5 million, before deducting placement agents’ fees and other offering expenses. A.G.P./Alliance Global
Partners and Boustead served as placement agents of this offering. The Company received  proceeds from the offering of approximately
$4.0 million, net of placement agent fees of $0.5 million.

Off-Balance
Sheet Arrangements

The
Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that are material to investors.

63

Critical
Accounting Policies and Significant Judgments and Estimates

This
discussion and analysis of our financial condition and results of operations is based on our  consolidated financial statements,
which have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The preparation
of these